Cancer diagnosis & prognosis最新文献_第9页

Laparoscopic Partial Splenectomy May Be Valuable for the Diagnosis of Malignant Lymphoma: A Case Report. 腹腔镜部分脾脏切除术可能对恶性淋巴瘤的诊断有价值：病例报告。

Cancer diagnosis & prognosis Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10360

Shinpei Ogino, Takeshi Ishimoto, Junshin Fujiyama, Masamichi Bamba, Mamoru Masuyama

{"title":"Laparoscopic Partial Splenectomy May Be Valuable for the Diagnosis of Malignant Lymphoma: A Case Report.","authors":"Shinpei Ogino, Takeshi Ishimoto, Junshin Fujiyama, Masamichi Bamba, Mamoru Masuyama","doi":"10.21873/cdp.10360","DOIUrl":"10.21873/cdp.10360","url":null,"abstract":"Background/aim: Diagnosing primary splenic malignant lymphoma (PSML) is challenging due to the non-specific nature of splenomegaly, necessitating splenic biopsy for confirmation. However, performing partial splenic resection for diagnostic purposes is an elective procedure due to the risk of major hemorrhage. Despite the longstanding practice of splenectomy over the past few decades, it remains invasive and may result in severe early or late complications. Hence, we present laparoscopic partial splenectomy (LPS) in a patient suspicious of PSML for diagnostic purposes in this study.Case report: An 81-year-old woman presented to our hospital with a one-month history of fever and dry cough. Atypical cells had been detected in her peripheral blood nine months ago. However, at that time, a bone marrow examination did not reveal any atypical cells. The laboratory tests revealed a soluble interleukin receptor-2 levels of 4,667 U/dl and atypical cells were also found in peripheral blood. Abdominal computed tomography showed splenomegaly without any other relevant findings. These findings are suspicious of PSML and LPS without vessel ligation was performed and a small fraction of the spleen from the inferior pole measuring 1.8×1.0 cm was resected. The operation lasted for 63 min with minimal estimated blood loss. Histopathological findings were compatible with the diagnosis of diffuse B-cell lymphoma. The postoperative clinical course was uneventful, and splenomegaly demonstrated improvement six months after the operation.Conclusion: LPS without vessel ligation for biopsy may be valuable for the diagnosis of malignant lymphoma, particularly when there are no swollen lymph nodes, as it offers a less invasive approach.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 4","pages":"534-538"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Successful Management of Upper Gastrointestinal Obstruction With Primary Advanced Ovarian Cancer. 成功治疗原发性晚期卵巢癌上消化道梗阻。

Cancer diagnosis & prognosis Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10347

Tomoe Yazaki, Ayumu Matsuoka, Shinichi Tate, Kyoko Nishikimi, Rie Okuya, Satoyo Otsuka, Kaori Koga, Hirokazu Usui

{"title":"Successful Management of Upper Gastrointestinal Obstruction With Primary Advanced Ovarian Cancer.","authors":"Tomoe Yazaki, Ayumu Matsuoka, Shinichi Tate, Kyoko Nishikimi, Rie Okuya, Satoyo Otsuka, Kaori Koga, Hirokazu Usui","doi":"10.21873/cdp.10347","DOIUrl":"10.21873/cdp.10347","url":null,"abstract":"Background/aim: Upper gastrointestinal obstruction is an extremely rare complication of primary ovarian cancer. We present a case of primary advanced ovarian cancer with gastroduodenal obstruction successfully managed with neoadjuvant chemotherapy (NAC) and conservative treatment.Case report: A 60-year-old woman was referred to our hospital for advanced ovarian cancer with upper gastrointestinal obstruction. Computed tomography and endoscopy revealed severe duodenal obstruction caused by dissemination. NAC was initiated with conservative management using a nasogastric tube and total parenteral nutrition (TPN). She was able to eat and TPN was stopped after three months. Complete resection was achieved with interval debulking surgery (IDS) not involving pancreatoduodenectomy, which would have been necessary for primary debulking surgery. There were no serious postoperative complications.Conclusion: NAC with conservative management can improve upper gastrointestinal obstruction in patients with primary advanced ovarian cancer. Furthermore, IDS is expected to allow complete resection, avoiding highly invasive surgeries.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 4","pages":"454-458"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215435/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 Treatment. Gleason模式5可能是镭-223治疗的预后因素。

Cancer diagnosis & prognosis Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10345

Mitsuhisa Nishimoto, Kazutoshi Fujita, Aritoshi Ri, Saizo Fujimoto, Yasuo Oguma, Shingo Toyoda, Mamoru Hashimoto, Takashi Kikuchi, Shogo Adomi, Yoshitaka Saito, Yasunori Mori, Takafumi Minami, Masahiro Nozawa, Kazuhiro Yoshimura, Makoto Hosono, Hirotsugu Uemura

{"title":"Gleason Pattern 5 May Be a Prognostic Factor in Radium-223 Treatment.","authors":"Mitsuhisa Nishimoto, Kazutoshi Fujita, Aritoshi Ri, Saizo Fujimoto, Yasuo Oguma, Shingo Toyoda, Mamoru Hashimoto, Takashi Kikuchi, Shogo Adomi, Yoshitaka Saito, Yasunori Mori, Takafumi Minami, Masahiro Nozawa, Kazuhiro Yoshimura, Makoto Hosono, Hirotsugu Uemura","doi":"10.21873/cdp.10345","DOIUrl":"10.21873/cdp.10345","url":null,"abstract":"Background/aim: Radium-223 treatment reduces the risk of death in patients with metastatic castration-resistant prostate cancer (CRPC). This study analyzed the prognostic factors in patients treated with radium-223 dichloride.Patients and methods: Patients who received radium-223 dichloride were retrospectively analyzed. Prostate-specific antigen (PSA) response and alkaline phosphatase (ALP) decline rates were analyzed. Overall survival (OS) was evaluated using Kaplan-Meier curves, and prognostic factors for OS were assessed using Cox proportional hazards analysis.Results: Fifty-six patients were included in the study. The five-year OS rate in patients after diagnosis of CRPC was 62.2% [95% confidence interval (CI)=27.55-112.45], while the five-year OS rate in patients at the initiation of radium-223 treatment was 21.3% (95%CI=17.20-36.79). Six patients (11.1%) had a >50% PSA decline rate, and 10 (17.9%) had a >50% ALP decline rate. Cox proportional hazards analysis showed that PSA levels at the initiation of radium-223 treatment [hazard ratio (HR)=1.00; 95%CI=1.00-1.00; p=0.0054] and Gleason Pattern (GP) 5 (HR=5.42; 95%CI=1.08-27.27; p=0.0400) were associated with OS. Patients with GP 5 had a significantly poorer prognosis compared with patients with a GP ≤4. Early administration of radium-223 as a first- or second-line treatment was not associated with OS compared with late administration of radium-223 as a third-line or later treatment.Conclusion: GP 5 and high PSA levels at radium-223 initiation were associated with worse OS. Radium-223 as first- or second-line treatment was not associated with OS. Therefore, a treatment strategy for CRPC based on GP 5 is needed.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 4","pages":"441-446"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215439/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Radiotherapy for Solitary Bony or Extramedullary Plasmacytoma. 单发骨性或髓外性浆细胞瘤的放射治疗。

Cancer diagnosis & prognosis Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10350

Atsuto Katano, Subaru Sawayanagi, Masanari Minamitani, Shingo Ohira, Hideomi Yamashita

{"title":"Radiotherapy for Solitary Bony or Extramedullary Plasmacytoma.","authors":"Atsuto Katano, Subaru Sawayanagi, Masanari Minamitani, Shingo Ohira, Hideomi Yamashita","doi":"10.21873/cdp.10350","DOIUrl":"10.21873/cdp.10350","url":null,"abstract":"Background/aim: This study aimed to determine the oncological outcomes associated with curative radiotherapy for solitary bony or extramedullary plasmacytomas by drawing on clinical data from a single tertiary center. This study aimed to provide a comprehensive understanding of the efficacy of radiotherapeutic interventions and delineate the patterns of disease recurrence.Patients and methods: Eleven consecutive patients diagnosed with solitary bony or extramedullary plasmacytomas and treated between May 2007 and November 2023 were retrospectively screened. Different radiotherapy doses and fractionations were employed, and statistical analyses were performed to assess overall survival (OS) and disease-free survival (DFS).Results: Among the 11 patients (9 males and 2 females), primary tumors were located within the bone in seven patients, whereas extramedullary tumors were observed in four patients. The median prescribed radiation dose was 46 Gy. The 5-year OS and DFS were 83.3% and 28.9%, respectively. Progression to multiple myeloma occurred in four patients with primary bony plasmacytoma. Local control rate was 88.9%, and one patient experienced distant metastasis after 32 months. Bony plasmacytoma has a high tendency of leading to multiple myeloma rather than extramedullary plasmacytoma (5-year progression to multiple myeloma-free survival rate, 20.8% vs. 100%, p=0.08).Conclusion: Radiotherapy is effective for solitary plasmacytomas with favorable local control and high objective response rates. A comparison with the existing literature supports the role of radiotherapy in the management of these conditions. The differences in outcomes between bony and extramedullary plasmacytomas emphasize the need for personalized treatment approaches.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 4","pages":"470-474"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215434/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy. 腹痛指数是接受全身化疗的转移性泌尿系统癌患者的预后指标

Cancer diagnosis & prognosis Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10351

Yoshihisa Mimura, Taku Naiki, Yosuke Sugiyama, Yoshihiko Tasaki, Kunihiro Odagiri, Toshiki Etani, Takashi Nagai, Moeko Iida, Yuka Kimura, Nanami Ito, Yuji Hotta, Takahiro Yasui, Yoko Furukawa-Hibi

{"title":"Cachexia Index Is a Prognostic Indicator in Patients With Metastatic Urothelial Carcinoma Treated With Systemic Chemotherapy.","authors":"Yoshihisa Mimura, Taku Naiki, Yosuke Sugiyama, Yoshihiko Tasaki, Kunihiro Odagiri, Toshiki Etani, Takashi Nagai, Moeko Iida, Yuka Kimura, Nanami Ito, Yuji Hotta, Takahiro Yasui, Yoko Furukawa-Hibi","doi":"10.21873/cdp.10351","DOIUrl":"10.21873/cdp.10351","url":null,"abstract":"Background/aim: Cancer cachexia is associated with poor prognosis in patients with metastatic urothelial carcinoma (mUC). The objective of the study was to assess the cachexia index (CXI), which is a new indicator assessing the status of cancer cachexia, as a prognostic indicator for mUC patients treated with gemcitabine plus cisplatin (GC) chemotherapy.Patients and methods: The study included 55 patients with mUC who underwent GC chemotherapy between 2008 and 2022 as first-line chemotherapy. The CXI at the start of chemotherapy was determined as follows: CXI=(serum albumin × skeletal muscle mass index)/ (neutrophil count/lymphocyte count). Patients were categorized into two groups based on a median CXI value (CXI-high and CXI low). We used Kaplan-Meier curves and multivariate Cox proportional hazards regression models to assess the association between the CXI and overall survival (OS).Results: At the start of GC chemotherapy, significant differences were not found in patients' characteristics. The median OS was significantly shorter in the CXI-low group [10.0 months (95% confidence interval (CI)=5.1-12.8)] than in the CXI-high group [22.3 months (95% CI=13.6-NA), p<0.05]. Multivariate analysis revealed that low CXI was a predictor of a poor prognosis [hazard ratio (HR)=2.25, 95% CI=1.12-4.52, p<0.05].Conclusion: CXI might be useful as a prognostic indicator for patients with mUC undergoing first-line GC chemotherapy.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 4","pages":"475-481"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215442/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma. 比较阿法替尼和奥希替尼对PD-L1阳性表皮生长因子受体突变非小细胞癌患者的疗效

Cancer diagnosis & prognosis Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10357

Minehiko Inomata, Yosuke Kawashima, Ryota Saito, Daisuke Morinaga, Hitomi Nogawa, Masamichi Sato, Yohei Suzuki, Satoru Yanagisawa, Takashi Kikuchi, Daisuke Jingu, Naruo Yoshimura, Toshiyuki Harada, Eisaku Miyauchi

{"title":"Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma.","authors":"Minehiko Inomata, Yosuke Kawashima, Ryota Saito, Daisuke Morinaga, Hitomi Nogawa, Masamichi Sato, Yohei Suzuki, Satoru Yanagisawa, Takashi Kikuchi, Daisuke Jingu, Naruo Yoshimura, Toshiyuki Harada, Eisaku Miyauchi","doi":"10.21873/cdp.10357","DOIUrl":"10.21873/cdp.10357","url":null,"abstract":"Background/aim: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective for treating non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, higher tumor programmed death ligand-1 (PD-L1) expression is associated with a poor response to EGFR-TKIs, and information on the comparison between afatinib and osimertinib in PD-L1-positive EGFR-mutant NSCLC is scarce.Patients and methods: We retrospectively analyzed data of patients with PD-L1-positive EGFR-mutant NSCLC to compare the effectiveness of afatinib and osimertinib.Results: A total of 177 patients were included in the study. The Cox proportion hazard model was adjusted for age, sex, performance status, EGFR mutation status, PD-L1 expression level, and brain metastasis, revealing that there was no significant difference in risk for progression [hazard ratio (HR)=0.99, 95% confidence interval (CI)=0.64-1.53] or death (HR=0.96, 95% CI=0.54-1.73) between afatinib and osimertinib.Conclusion: In conclusion, the EGFR-TKI treatment duration and overall survival after the treatment with afatinib or osimertinib were similar in patients with PD-L1-positive EGFR-mutant NSCLC in the present study.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 4","pages":"515-520"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215441/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation. 表皮生长因子受体（EGFR）突变的 G-CSF 肺癌的治疗耐药性

Cancer diagnosis & prognosis Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10359

Koki Ito, Kyoichi Kaira, Hisao Imai, Ayako Shiono, Kosuke Hashimoto, O U Yamaguchi, Hiroshi Kagamu

{"title":"Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation.","authors":"Koki Ito, Kyoichi Kaira, Hisao Imai, Ayako Shiono, Kosuke Hashimoto, O U Yamaguchi, Hiroshi Kagamu","doi":"10.21873/cdp.10359","DOIUrl":"10.21873/cdp.10359","url":null,"abstract":"Background/aim: Granulocyte colony-stimulating factor (G-CSF)-producing neoplasms are relatively rare; however, little is known on the clinical features of G-CSF-producing lung cancer harboring activating epidermal growth factor receptor (EGFR) mutations.Case report: A 66-year-old female was definitively diagnosed with G-CSF-producing lung cancer that was positive for EGFR mutations. She repeatedly received epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as osimertinib and afatinib. However, she developed resistance to these molecular-targeting drugs within 2 to 3 months after immediate shrinkage. Thus, the patient was treated with chemoimmunotherapy including bevacizumab, and demonstrated a slight survival benefit.Conclusion: Overall, G-CSF-producing lung cancers positive for EGFR mutations were resistant to different treatment modalities. Clinicians should be attentive to the potential resistance of G-CSF-producing EGFR mutant lung cancer to EGFR-TKI therapy.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 4","pages":"529-533"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215452/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Age Is a Risk Factor for Olaparib Dose Modification and Discontinuation in Patients With Ovarian Cancer. 年龄是卵巢癌患者奥拉帕利剂量调整和停药的一个风险因素

Cancer diagnosis & prognosis Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10346

Hiroaki Inui, Masayasu Sato, Hiroyuki Yoshida

{"title":"Age Is a Risk Factor for Olaparib Dose Modification and Discontinuation in Patients With Ovarian Cancer.","authors":"Hiroaki Inui, Masayasu Sato, Hiroyuki Yoshida","doi":"10.21873/cdp.10346","DOIUrl":"10.21873/cdp.10346","url":null,"abstract":"Background/aim: Olaparib, a poly (ADP-ribose) polymerase inhibitor, is widely used as maintenance therapy for ovarian cancer. Dose modification, such as dose reduction and treatment interruption, are frequently performed to manage adverse events (AEs) of olaparib. By identifying patients at high risk for dose modification before administration, interventions related to appropriate control of AEs can be implemented. This study aimed to evaluate risk factors of olaparib dose modification and its clinical usefulness.Patients and methods: Sixty patients with ovarian cancer who received olaparib were included in this retrospective cohort study. Associations between patients' characteristics and dose modification were evaluated by multivariate logistic regression analysis. We also examined whether risk factors of dose modification were associated with treatment discontinuation due to AEs.Results: Twenty-five (41.7%) patients required dose modification. Patients who required dose modification were significantly older (p=0.018) and tended to be more underweight (p=0.078) than those who did not require dose modification. In multivariate analysis, increasing age was significantly associated with dose modification (odds ratio=1.056; 95% confidence interval=1.002-1.112; p=0.034). The optimal cutoff of age as a risk factor for dose modification, calculated from receiver operating characteristic curves, was 65.0 years. Patients aged 65.0 years and older were significantly more likely to discontinue olaparib owing to AEs (p=0.0437).Conclusion: Age is a risk factor of olaparib dose modification due to AEs. Older patients, who frequently require dose modification, are more likely to discontinue olaparib, suggesting that strict management of AEs is particularly necessary in this patient group.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 4","pages":"447-453"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215453/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

BMP Signaling Is a Prognostic Marker in Patients With Colorectal Cancer and Associates With Frailty. BMP 信号转导是结直肠癌患者的预后标志，并与体质虚弱有关。

Cancer diagnosis & prognosis Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10341

Shohei Sawata, Shota Shimizu, Yoshiaki Matsumi, Yusuke Kono, Kyoichi Kihara, Manabu Yamamoto, Teruhisa Sakamoto, Yoshihisa Umekita, Yoshiyuki Fujiwara

{"title":"BMP Signaling Is a Prognostic Marker in Patients With Colorectal Cancer and Associates With Frailty.","authors":"Shohei Sawata, Shota Shimizu, Yoshiaki Matsumi, Yusuke Kono, Kyoichi Kihara, Manabu Yamamoto, Teruhisa Sakamoto, Yoshihisa Umekita, Yoshiyuki Fujiwara","doi":"10.21873/cdp.10341","DOIUrl":"10.21873/cdp.10341","url":null,"abstract":"Background/aim: Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β superfamily of ligands and have been shown to promote or suppress colorectal cancer (CRC) growth. Developing treatments that target BMPs is challenging due to their multiple roles, including involvement in the inflammatory response and nutritional status. The present study evaluated the prognostic value of BMP-4, which is believed to be highly expressed in CRC, and its correlation with inflammatory and nutrition statuses in patients with CRC.Materials and methods: We analyzed BMP-4 expression in tumor tissues from 144 patients who underwent CRC surgery using immunohistochemistry and evaluated the relationship between BMP-4 levels and clinical outcomes.Results: Kaplan-Meier analysis revealed that patients with high expression levels of BMP-4 exhibited a shorter overall survival rate than those with low levels of expression. Multivariate analysis revealed that BMP-4 expression was an independent prognostic factor for overall survival and death from other diseases in CRC patients. Furthermore, high BMP-4 expression was significantly correlated with high C-reactive protein/Albumin ratio, sarcopenia, and osteopenia.Conclusion: BMP-4 is a significant prognostic factor in CRC, particularly in predicting death from other diseases, while also showing associations with inflammatory and nutritional statuses.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 4","pages":"416-423"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215445/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tubular Carcinoma of the Breast: The Possibility to Omit Sentinel Lymph Node Biopsy. 乳腺管状癌：省略前哨淋巴结活检的可能性。

Cancer diagnosis & prognosis Pub Date : 2024-07-03 eCollection Date: 2024-07-01 DOI: 10.21873/cdp.10344

Sae Yamane, Akira Matsui, Ayako Nakashoji, Manami Sasahara, Yuya Murata, Takayuki Kinoshita

{"title":"Tubular Carcinoma of the Breast: The Possibility to Omit Sentinel Lymph Node Biopsy.","authors":"Sae Yamane, Akira Matsui, Ayako Nakashoji, Manami Sasahara, Yuya Murata, Takayuki Kinoshita","doi":"10.21873/cdp.10344","DOIUrl":"10.21873/cdp.10344","url":null,"abstract":"Background/aim: Tubular breast carcinoma, classified as a special type of invasive cancer, has a good prognosis. This study aimed to retrospectively investigate the clinical and pathological characteristics of 32 tubular carcinoma cases enrolled at our institution, with a focus on exploring the potential for treatment de-escalation.Patients and methods: The study included all patients diagnosed with tubular breast carcinoma at our hospital between January 2005 and December 2021. In addition, 549 patients with ductal carcinoma in situ (DCIS) and 1,524 patients with stage I and II invasive cancers [not otherwise specified (NOS)] were selected for comparison.Results: All participants were female, with an average age of 54.4 years. The median follow-up duration was 64 months. The median tumor diameter was 7 mm, and all cases were Luminal A type. Moreover, no lymph vascular invasion was observed in any case, and no local recurrence, distant metastasis, or death occurred. The sentinel lymph node positive rate was 0% in the tubular carcinoma group, significantly lower than that in the NOS group (25.5%, p=0.0019) and not significantly different from that in the DCIS group (0.2%). The tubular carcinoma group tended to have better overall survival (OS) and disease-free survival (DFS) than the NOS group. Furthermore, the tubular carcinoma group was not inferior in OS and DFS compared to the DCIS group.Conclusion: Lymph node metastasis rate, OS, and DFS of the tubular carcinoma group are comparable to those of the DCIS group. Sentinel lymph node biopsy for tubular carcinoma can be omitted with an accurate preoperative diagnosis.","PeriodicalId":72510,"journal":{"name":"Cancer diagnosis & prognosis","volume":"4 4","pages":"434-440"},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0